Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD10 for Early Stage Hodgkin Lymphoma
NCT00265018Phase 3Completed
- Sponsor
- University of Cologne
- Start
- May 1998
- Primary completion
- Jan 2003
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, bleomycin, vinblastine and dacarbazine in Hodgkin lymphoma (HL) (4 arms), sponsored by University of Cologne. Primary endpoints: Progression-Free Survival at 5 years and Freedom From Treatment Failure at 5 years. Started May 1998; status: completed.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00265018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265018.